Is tirzepatide still on the FDA drug shortage list?
Is tirzepatide still on the FDA shortage list?
No. As of Nov 15, 2026, FDA’s drug shortage data, read through openFDA, lists no tirzepatide product with status “Current.” FDA’s Drug Shortages Database page for Tirzepatide Injection shows the status “Resolved.” FDA determined the tirzepatide injection shortage resolved on Dec 19, 2024, after first listing it on Dec 15, 2022.
Checked Nov 15, 2026 against FDA’s drug shortage data through openFDA, and Nov 15, 2026 against FDA’s Drug Shortages Database page for Tirzepatide Injection. Shortage status can change; FDA’s database is the current word.
Tirzepatide on FDA’s shortage list, by date
| FDA’s words or record | Source | ||
|---|---|---|---|
| Dec 15, 2022 | Listed | “Tirzepatide injection products were first added to FDA’s drug shortage list on December 15, 2022.” | FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound) |
| April 2024 | Listed | “The Zepbound pen products were approved by FDA in November 2023 (NDA 217806) and added to FDA’s drug shortage list in April 2024 due to high demand.” | FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound) |
| Oct 2, 2024 | Resolved | “The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. Tirzepatide injection has been in shortage since 2022 due to increased demand.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Oct 22, 2024 | Litigation | “As part of litigation, the decision to remove tirzepatide from the FDA drug shortage list has been remanded to the agency for reevaluation.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Dec 19, 2024 | Resolved | “This order revokes and replaces FDA’s October 2, 2024 decision on the same subject. I. Determination FDA determines that the tirzepatide injection product shortage is resolved.” | FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound) |
| Feb 18, 2025 | 503A grace period end | “For state-licensed pharmacists or physicians compounding under section 503A of the FD&C Act, 60 calendar days from the date of this order, until February 18, 2025” | FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound) |
| Mar 5, 2025 | Litigation | “On March 5, 2025, the district court denied the plaintiffs’ preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:24-cv-00953 (N.D. Tex.).” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
| Mar 19, 2025 | 503B grace period end | “For outsourcing facilities under section 503B of the FD&C Act, 90 calendar days from the date of this order, until March 19, 2025.” | FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound) |
| Apr 1, 2026 | Status statement | “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.” | FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize |
FDA’s most recent statement
- Apr 1, 2026: FDA stated that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list. FDA explained that outsourcing facilities may compound from bulk drug substances only if the substance is on the 503B bulks list or the drug is on the shortage list at the time of compounding, distribution and dispensing. Source: FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
What the end of the shortage meant for compounding
FDA set dates after which it would act on compounding that depended on tirzepatide being in shortage: February 18, 2025 for state-licensed pharmacies and physicians (section 503A) and March 19, 2025 for outsourcing facilities (section 503B). The rules FDA states now are on Is compounded tirzepatide still legal?. All GLP-1 drugs: shortage history.
Common questions
When was tirzepatide added to the shortage list?
FDA’s December 19, 2024 order says tirzepatide injection products were first added on December 15, 2022, with the Zepbound pens added in April 2024.
When did FDA say the tirzepatide shortage was resolved?
October 2, 2024, and again on December 19, 2024 after a court sent the first decision back to FDA for reevaluation.
Sources
- FDA Declaratory Order, February 21, 2025: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy)
- FDA Declaratory Order, December 19, 2024: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound)
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA drug shortage data, via openFDA drug shortages endpoint
- FDA Drug Shortages (via openFDA drug shortages endpoint)
- FDA Drug Shortages Database: Tirzepatide Injection
Records last pulled Nov 15, 2026. Every entry links to the original public record.